Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. News
  7. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaxcyte : Investor Presentation September 2021

09/20/2021 | 08:42pm EST

Corporate Presentation

September 20, 2021

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include but are not limited to, statements related to the benefits of Vaxcyte's vaccine candidates; the process and timing of anticipated future development of Vaxcyte's vaccine candidates, including the timing and submission of an IND application for VAX-24 and the initiation of the VAX-24 Phase 1/2 clinical proof-of-concept study thereafter; the timing and availability of topline data for VAX-24; the ability to complete the manufacturing of the GMP drug product; the achievement of future funding milestones; the use and availability of funds from CARB-X; the initiation of IND-enabling activities for VAX-A1 and the nomination of a final vaccine candidate for VAX-PG; the market opportunity for our vaccines; our expectations regarding the potential benefits, spectrum coverage and immunogenicity of our vaccine candidates; the timing of the initiation, progress and expected results of our preclinical studies, clinical trials and research and development plans; and other statements that are not historical fact. The words "anticipate," "believe," "continue," "could," "designed," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are based on Vaxcyte's current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte's product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; Vaxcyte's reliance on third-party manufacturers; potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates; the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; sufficiency of cash and other funding to support Vaxcyte's development programs and other operating expenses; and the ongoing COVID-19 pandemic, which could materially and adversely affect Vaxcyte's business and operations. These and other risks are described more fully in Vaxcyte's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward- looking statements contained in this release as a result of new information, future events or changes in its expectations.

2

Vaxcyte Mission Statement

Seeking to improve global health by developing

superior & novel vaccines designed to prevent or treat

some of the most common & deadly infectious

diseases worldwide.

3

Key Corporate Highlights

Next-Generation Vaccine Company - Led by Pneumococcal Conjugate Vaccine (PCV) Franchise

Large Market

Opportunity for PCV

Franchise

Cell-Free

Protein Synthesis

Platform

Disciplined

Robust

Aligned

Target

Development

Critical

Selection

Pipeline

Resources

  • Scalable PCV platform enabling broader-spectrumPCVs: VAX-24& VAX-XP
  • Lead candidate: VAX-24
    • 24-valentPCV with potential to replace SOC
    • Anticipated IND filing in Jan-Jun '22(1)
    • Anticipated Phase 1/2 data readout in late '22- early '23(1)

4 (1) Guidance provided as of August 11, 2021.

  • Leverages site- specific conjugation
  • Permits production of
    "tough-to-make" antigens
  • Demonstrated speed, flexibility, and scalability

• Targets well-defined

• Platform unlocks large

>$7B market segment

market opportunities:

• Honors well-

- VAX-A1: Novel Group A

understood PCV MOA

Strep conjugate vaccine

• Leverages established

- VAX-PG: Novel

surrogate immune

periodontitis therapeutic

endpoints and clinical

vaccine

pathways

  • Strategic alignment with Lonza (manufacturing)
  • Seasoned management team, directors and advisors
  • IPO in June 2020
  • Cash, cash equivalents and investments of $341.0M at 6/30/21

Experienced Team, Board of Directors, and Scientific Advisors

Outstanding Track Record in Vaccines and Biopharma

Management Team

Grant Pickering, MBA

Jim Wassil, MS, MBA

Andrew Guggenhime,

CEO & Co-founder

COO

MBA

President & CFO

Jeff Fairman, PhD

Paul Sauer, MBA

VP Research &

SVP PD & Manufacturing

Co-founder

Board of Directors

Kurt von Emster

Peter Hirth, PhD

Heath Lukatch, PhD

Interim Chairman

Halley Gilbert

Annie Drapeau

Teri Loxam

Grant Pickering

Scientific Advisory Board

Jeff Almond, PhD

Tony Ford-Hutchinson,

Bill Hausdorff, PhD

PhD

Tom Monath, MD

Emmanuel Walter,

MD, MPH

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Vaxcyte Inc. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 00:41:01 UTC.


ę Publicnow 2021
All news about VAXCYTE, INC.
11/11Vaxcyte to Present at Upcoming Investor Conferences
GL
11/10Vaxcyte Investor Presentation November 2021
PU
11/10Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update - For..
PU
11/10Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
GL
11/10VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
10/28VAXCYTE, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/28Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
AQ
10/28Vaxcyte, Inc. Announces Board Changes
CI
10/22INSIDER SELL : Vaxcyte
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -101 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,96x
Yield 2021 -
Capitalization 1 020 M 1 020 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 1 020x
Nbr of Employees 58
Free-Float 84,3%
Chart VAXCYTE, INC.
Duration : Period :
Vaxcyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXCYTE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 19,32 $
Average target price 50,50 $
Spread / Average Target 161%
EPS Revisions
Managers and Directors
Grant E. Pickering Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
Carlos V. Paya Chairman
Romulo Colindres Chief Medical Officer
Jim Wassil Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VAXCYTE, INC.-27.29%1 020
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819